Nov 10 (Reuters) - Briacell Therapeutics Corp BCT.V :
* BriaCell provides clinical development update on BriaVax(TM)
* To only use BriaVax newly generated by UC Davis Good Manufacturing Practice Facility in upcoming Phase I/IIA clinical trial
* Expects testing results for material intended to dose first patient in late December 2016, for clinical trial to initiate mid-late Q1 2017 Source text for Eikon: Further company coverage: BCT.V